Recent developments in the medical and surgical treatment of melanoma |
| |
| Authors: | Jonathan S. Zager MD Ragini R. Kudchadkar MD |
| |
| Affiliation: | 1. Director of Regional Therapies, Associate Professor, and Associate Member, Department of Cutaneous Oncology, Moffitt Cancer Center, University of South Florida, , Tampa, FL;2. Assistant Professor of Oncologic Sciences and Assistant Member, Department of Cutaneous Oncology, Moffitt Cancer Center, University of South, , Florida, Tampa, FL |
| |
| Abstract: | Answer questions and earn CME/CNE Increasing knowledge of the biology of melanoma has led to significant advances in drug development to fight this disease. Surgery is the primary treatment for localized disease and is an integral part of management in patients with more advanced disease. The last decade has become the era of targeted therapy in melanoma and has revolutionized the treatment of this disease. Since 2011, 4 new agents have been approved for the treatment of patients with metastatic melanoma: ipilimumab, vemurafenib, dabrafenib, and trametinib. Several new agents are currently in phase 3 trials with hopes of even more agents being approved for this once “untreatable” disease. How to integrate surgical options with more effective systemic therapies has become a new challenge for physicians. This review will provide an update on current surgical options, highlight the pathway to the development of the newly approved agents, and further discuss new treatments that are on the horizon. CA Cancer J Clin 2014;64:171–185. © 2014 American Cancer Society. |
| |
| Keywords: | melanoma surgical oncology medical oncology molecularly targeted therapies immunotherapy |
|
|
